Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

NCT01960023 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

NETWORK

Sponsor class

Stopped This registry was planned to report on the Phase II portion of the study. NSABP decided not to proceed with the Phase II portion of the study.

Conditions

Colorectal Cancer

Interventions

DRUG: Cetuximab
DRUG: Neratinib

Sponsor

NSABP Foundation Inc